I try to pick up credible info from this board. I rarely post. I wanted to paste the following chart for the rookies, myself included. Could it be possible that companies that have a vested interest in seeing their drug continue to prosper might poke holes in anything that may challenge those sales? As you can see from this chart Novolog has a nice little racket going here. If Mannkind and Afrezza penetrate this market what would happen to the sales of Novolog? There are some very smart people involved with making sure Afrezza does not go to market. There are billions of dollars at stake. So who is actually writing these hit pieces? What are they being paid to write them? What if the two drugs do not show bioequivalence? Does it matter if afrezza is not as effective as Novolog? or can the drug still pass the FDA because it will improve medical adherence? Estimates from the World Health Organization (2003) indicate that only about 50% of patients with chronic diseases living in developed countries follow treatment recommendations.^[1] In particular, low rates of adherence to therapies for asthma, diabetes, and hypertension are thought to contribute substantially to the human and economic burden of those conditions.ISn't this what really matters? Who wins this game, Al Mann and Mannkind shareholders, or Big Pharma?

Novolog Sales Data

Rank40
Currentsalesrank, all
U.S.Pharmaceuticals.

Last updated:August 2013 (updated quarterly).
The followingdatashowsNovologU.S. retail sales in Q2 2013 compared to previous quarters.

Date RangeSales RankSales ($000) Units (000)

Q2 2013
40 (2)
$319,752
-0.94%
2,975
-2.14%

Q1 2013
42 (3)
$322,779
3.74%
3,040
-10.03%

Q4 2012
39 (5)
$311,150
5.87%
3,379
8.54%

Q3 2012
44 (10)
$293,893
8.83%
3,113
3.53%

Q2 2012
54 (3)
$270,047
1.41%
3,007
0.91%

Q1 2012
57 (6)
$266,305
5.67%
2,980
3.72%

Q4 2011
63 (3)
$252,015
0.97%
2,873
-0.48%

Q3 2011
60 (1)
$249,591
-0.96%
2,887
-2.66%

Q2 2011
61 (5)
$252,010
3.16%
2,966
-0.70%

Q1 2011
66
$244,297

2,987

I don't post often but I have a large position. Is this a game or what?

Now every news wire says Afrezza (and Dreamboat) will have positive trial results yet we all need to be concerned about approval? It seems to me if results are good (meet end points) we should celebrate. No?

Is the "good news" already priced in? I guess the news of a partnership is the next "event" to push this thing higher.

I am long and will continue to hold. Just wanted to jump in and comment.

GLTA!

Yes picked up 1200 more at 7.40.

Thanks Liahall, this is why I love this board. So much good info. Good luck to all. :-)

I have been following this board for months so thank you all for the wealth of knowledge on the company and stock. I have been accumulating MNKD since it was hovering around 4. I was hoping someone could help refute the negative article below. I trust that most "regulars" here have/had seen this article published in April, 2013. Thanks in advance for any help.

http://www.smallcapnetwork.com/MannKind-s-Afrezza-Likely-to-Fail-AFFINITY-1-Phase-III-Trial/s/via/16571/article/view/p/mid/1/id/111/